Abstract:Introduction Practice guidelines for resection of surgical candidates in pancreatic adenocarcinoma are consensus-driven to ensure patients receive standardized care, but current evidence regarding peri-operative strategies regarding systemic and chemoradiation treatment is based on retrospective and metanalysis, which may lead to wide variation in implementation. Methods We used a database containing deidentified data patients with pancreatic adenocarcinoma who received surgical resections across five California academic medical centers to assess peri-operative outcomes and treatment strategies. We identified length of post-operative stay, rates of post-surgical hospital readmissions, pre-operative CA19-9 values, rates, type, duration and amount of neo-adjuvant, adjuvant, and chemoradiation therapy using structured data from EMR records at these sites. ANOVA, t-test and fisher exact tests were used to determine statistical significance of differences across institutions. Cox regression models were used to determine significance in survival differences between populations. Results. We identified 2,564 patients with PDAC diagnosis who had a surgical resection of the pancreas across five University of California sites. 1948 received pancreaticoduodenectomy, 549 received distal pancreatectomies, and 67 received total pancreatectomies. Median LOS was 8.0 days, with 7-day, 30-day, and 90-day readmission rates of 7.6, 17.7 and 23.2% respectively. There were significant differences in these rates across the five medical centers, though no association with site volume. Rate of completion of 6 months of peri-operative 5-FU based systemic therapy was 62% across all sites, but only 47% for 12 cycles of FOLFIRINOX. Patients receiving at least some NAC therapy more likely to complete the recommend six months than those who did not get any systemic therapy prior to surgical resection (77.8% vs 49.3%, p-value<0.001, Logistic regression with Wald test for significance). There were significant differences in the timing of peri-operative therapy across the sites, as well as the frequency of using pre- and post-operative chemo-radiation. Pre-operatively CA19-9, as well as use of perioperative Gemcitabine/Abraxane or FOLFIRINOX over Gemcitabine monotherapy were significant predictors of overall survival. Conclusion Post-operative length of stay and readmission rates were significantly different across these institutions, suggesting differential efficacy in supportive care strategies. Similarly, there is significant variation of peri-operative systemic therapy strategies. Patients receiving neoadjuvant systemic therapy are significantly more likely to complete the guideline recommended six months of treatment. Rates of peri-operative chemoradiation were significantly different across medical centers, without corresponding difference in overall survival. By comparing practice differences across institutions, we may better understand how these differences affect efficacy. Citation Format: Travis Zack, Amir Ashraf-Ganjouei, Kurt Giles, Mohammed Adam, Julian Hong, Margaret Tempero, Eric Collisson. Management of resectable pancreatic adenocarcinoma: Results from a data-driven approach across University of California system [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C070.

Surgery and Combined Transplant with Chemotherapy Improve Survival for Patients with Liver Limited and Locally Advanced Intrahepatic Cholangiocarcinoma: a Seer Database Analysis

Comparison of Therapeutic Effects of Chemoradiation, 125I Seed Implantation Combined with Chemotherapy and Chemotherapy Alone in Locally Advanced Pancreatic Cancer

Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery

Long-term Outcomes of Surgical Treatment for Pancreatic Neuroendocrine Neoplasm with Synchronous Hepatic Metastasis: A Multicenter Retrospective Cohort Study

Abstract C070: Management of resectable pancreatic adenocarcinoma: Results from a data-driven approach across University of California system

Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis

Comparison of neoadjuvant treatment modalities for locally advanced intrahepatic cholangiocarcinoma.

ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? an International Multi-center Study.

The Effect of Primary Site, Functional Status and Treatment Modality on Survival in Gastroenteropancreatic Neuroendocrine Neoplasms with Synchronous Liver Metastasis: a US Population-Based Study

Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection

A retrospective analysis on survival factors of transarterial chemoembolization for patients of pancreatic carcinoma with liver metastasis

Effect of Neoadjuvant Radiotherapy on Survival of Non-Metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis

Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database

Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Surgical Resection of Primary Tumor Improves Survival of Pancreatic Neuroendocrine Tumor with Liver Metastases.

Survivals of Patients with Surgically Treated and High-grade Pancreatic Neuroendocrine Carcinomas: A Comparative Study Between Two American Joint Committee on Cancer 8th Tumor-Node-metastasis Staging Systems.

Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer

Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database

Outcomes of Primary Tumor Resection in Patients with Stage IV Pancreatic Neuroendocrine Neoplasms: A Population-Based Survival Analysis